

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

CEPHALON, INC.

v.

EAGLE PHARMACEUTICALS, INC.

)
)
)
)
)

Civil Action No. _____

**SUPPLEMENTAL INFORMATION FOR PATENT CASES
INVOLVING A NEW DRUG APPLICATION (NDA)¹**

Plaintiff hereby provides the information below with respect to the deadlines set forth in 21 U.S.C. 355(j):

Date Patentee(s) Received Notice: September 17, 2013

Date of Expiration of Patent: March 26, 2029

Thirty Month Stay Deadline: March 17, 2016

10-21-2013

Date

/s/ John W. Shaw (No. 3362)

Attorney for Plaintiff

¹ This Hatch-Waxman case was triggered by plaintiff's receipt of defendant's Paragraph IV notice letter regarding its filing with the FDA of a NDA, rather than an ANDA. See 35 U.S.C. § 355(b)(2)(A)(iv); 35 U.S.C. § 355(c)(3)(C).